Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

NCT04439305 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped zero accrual

Conditions

Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Plasma Cell Myeloma

Interventions

DRUG: Dasatinib

Sponsor

National Cancer Institute (NCI)